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Abstract
Background: The lungs are involved in up to 70% of cases of leptospirosis. In the more severe forms-bleeding
from the lungs and acute respiratory distress syndrome-the lethality is high. The treatment proposed for
leptospirotic pneumonitis includes just care for patients in critical condition. Clinical and experimental studies point
to the involvement of immunological mechanisms in the physiopathology of lung damage caused by leptospirosis.
The aim of this study is to evaluate pulse treatment with methylprednisolone × placebo for leptospirotic
pneumonitis.
Study design: This is a randomized double-blind clinical trial to test the efficacy of pulse treatment with
methylprednisolone in patients with leptospirotic pneumonitis, compared with a placebo. The patients are
recruited from three hospitals in the city of Recife, in the Brazilian State of Pernambuco. The exclusion criteria
include patients aged under 15 years, a history of hypersensitivity to the use of corticosteroids, the presence of
active infection of fungal, tuberculous or bacterial origin apart from the infection by leptospira itself, the presence
of hemoconcentration or atypical lymphocyte count on admission to hospital, the presence of co-morbidities that
could be responsible for the radiological and gasometric alterations used to diagnose leptospirotic pneumonitis,
evidence of recent cranial trauma, neurosurgery, peptic ulcer, and participation in another clinical trial. The patients
are followed until they are discharged from hospital or die. The intervention consists of endovenous pulse
treatment with 1 g methylprednisolone for three consecutive days in the study group and a placebo in the control
group. The primary end-point is mortality from leptospirotic pneumonitis. The secondary end-points are: evolution
of lung disease; the occurrence of nosocomial respiratory infection; duration of mechanical ventilation; duration of
intensive care unit (ICU) stay; duration of hospital stay; occurrence of other infection-related complications; other
respiratory complications; and adverse effects of methylprednisolone. The study is designed to recruit 266 patients
and has a statistical “power” of 80% to detect a 50% reduction in mortality.
Discussion: Lung involvement in leptospirosis is a serious manifestation, with a high and variable mortality rate.
There is still no specific clearly-established treatment. Well-designed studies are needed to pave the way towards
development of such a treatment.
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Leptospirosis is an acute febrile infectious disease, which
is potentially seriously and found all over the world. It is
caused by spirochetes of the genus Leptospira [1]. In
Brazil, it is a serious public health problem [2,3]. Clini-
cal manifestations of leptospirosis are variable, ranging
from sub-clinical infection or anicteric and self-limited
fever to severe and potentially lethal disease with mas-
sive pulmonary hemorrhage or acute adult respiratory
distress syndrome (SARA) [3-5]. The lungs are involved
in leptospirosis in 16 to 70% of cases in different series
and the frequency of such involvement has been on the
rise and is becoming the main cause of death from the
disease, in Brazil and in other countries [5,6]. Mortality
rates for severe lung involvement may be as high as 50%
[7]. Current treatment for leptospirotic pneumonitis is
restricted to the basic care provided for patients in a cri-
tical condition [7,8]. The pathogenesis of such involve-
ment has not yet been clearly established, although
knowledge of the physiopathology of leptospirotic pneu-
monitis suggests the participation of immunological
mechanisms in the development of pulmonary forms of
the disease [9,10]. Two principal mechanisms have been
suggested: vasculitis mediated by toxins and an exagger-
ated immune response in the host [11-14]. On the basis
of evidence that immunological mechanisms are
involved in the pathogenesis of lung involvement, high
doses or a pulse of dexametasone or methylprednisolone
have been used in patients with severe lung involvement
in leptospirosis [15-17]. The aim of this article is to
describe the design and methods to be used for a rando-
mized double-blind clinical trial to evaluate the use of
pulse treatment with methylprednisolone compared with
a placebo in patients with lung involvement in
letptospirosis.
Methods/Design
Study design
The study is a double-blind randomized clinical trial -
RCT–w h i c he v a l u a t e st h ee f f i c a c yo ft h eu s eo fp u l s e
therapy with methylprednisolone compared to a placebo
in patients with lung involvement in leptospirosis. The
patients are randomly divided into two clearly-defined
groups: a) the study group, which receives conventional
treatment associated with endovenous pulse therapy
with 1 g methylprednisolone for three consecutive days
and b) the control group, which receives the conven-
tional treatment plus a placebo. The patients are fol-
lowed until such a time as they are discharged from
hospital or die. The primary endpoint is taken to be
mortality from leptospirotic pneumonitis. The secondary
end-points are: a) evolution of lung disease; b) the
occurrence of nosocomial respiratory infection; c) dura-
tion of mechanical ventilation; d) duration of intensive
care unit (ICU) stay; e); duration of hospital stay; f)
occurrence of other infection-related complications; h)
Other respiratory complications; and i) adverse effects
of methylprednisolone.
Definition of Terms
Diagnosis of Leptospirosis
Patients are diagnosed as having leptospirosis when they
present epidemiological information relating to contact
with flooded areas or professional exposure; clinical cri-
teria include the sudden onset of fever and myalgia; and
three of the following laboratory criteria: normal leuko-
metry or leukocytosis, thrombocytopenia, hyperbilirubi-
nemia, increased muscle enzymes and the absence of
hyperkalemia. Diagnosis of leptospirosis is confirmed by
a serological test (antibody count using the ELISA
method) collected after the seventh day and repeated
after the tenth day if necessary.
Diagnosis of Leptospirotic pneumonitis
Diagnosis of leptospirotic pneumonitis is based on the
presence of pulmonary interstitial infiltrate or bilateral
alveolar-interstitial infiltrate on chest x-ray, in associa-
tion with at least one of the following findings: altera-
tions found by lung auscultation (fine crackles), cough,
dyspnea, drop in hemoglobin, hemoptoic sputum,
hemoptysis and hypoxemia, the latter being defined as a
partial pressure of oxygen (PaO2) of less than 60 mmHg
in arterial gasometry or peripheral saturation of hemo-
globin with oxygen (SpO2)o fl e s st h a n9 0 %o np u l s e
oximetry, both under ambient conditions, or an oxyge-
nation índex (relation between PaO2/FiO2) of <300
mmHg.
Definition of Variables
Independent Variable
The main intervention was the exposure to corticosteroid.
Dependent Variables
The dependent variables used to evaluate the primary
and secondary outcomes are listed below in Table 1.
Table 1 Dependents variables to evaluate the primary
and secondary outcomes
Primary outcome Mortality
Secondary
outcomes
Evolution of lung disease
Nosocomial respiratory infection
Duration of mechanical ventilation
Duration of intensive care unit stay
Duration of hospital stay
Occurrence of other infection-related
complications
Other respiratory complications
Adverse effects of methylprednisolone
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The mortality outcome is defined as death caused lep-
tospirosis related or not to leptospirotic pneumonitis.
Evolution of lung disease
The evolution of leptospirotic pneumonitis is evaluated
by way of lung auscultation, radiological evaluation,
gasometric evaluation and hematometry (hematocrit and
hemoglobin) on a daily basis up to the seventh day and
then on the 14th and 28th days. Respiratory auscultation
is used to determine the presence of crackles. Once
these have been identified, their severity is classified
according to the extent of lung involvement (Table 2).
A lung auscultation is carried out again on the fifth
day of the patient’s follow-up and categorized according
to whether it is improving or worsening. It is considered
to be improving when there is a reduction in the para-
meters described above and considered to be worsening
if there is no change or if there has been an increase in
the parameters.
The radiological evaluation aims to determine the pre-
sence and the extent of pulmonary infiltrate. When pre-
sent, it is categorized according to its extent and
severity (Table 3).
Another radiological examination is carried out on the
fifth day of the patient’s follow-up and categorized as
improving or worsening. It is considered to be improv-
ing when there is a decline in the radiological para-
meters described above. It is considered to have
worsened when the parameters have remained
unchanged or seen an increase.
In the gasometric evaluation the relation between
PaO2/FiO2 is used in order to establish whether there
has been an improvement or a decline. It is measured
again on the fifth day and categorized as having
improved when the value is equal to or greater than 300
and as having declined when the value is less than 300.
The evolution of hematometry is measured by way of
hematocrit and hemoglobin levels and considered when
there is a decrease of over three percentage points in
hematocrit and 1 g/dl in hemoglobin, with no evidence
of blood loss. The intensity of bleeding from the lungs
is categorized as slight, when the hematocrit loss is
more than three and less than five percentage points,
moderate when greater than five but less than ten per-
centage points, and severe when it is greater than ten
percentage points. The evolution of hematometry is
evaluated on the fifth day of the patient’s follow-up and
is categorized as having improved when there has been
no drop in hematometry or when it is kept in levels
considered acceptable, when blood transfusion is neces-
sary. It is considered to have declined when the hemato-
metry remains unchanged after hemotransfusion or
when there is an increased drop in hematometry.
Patients are considered to have improved, irrespective
of the extent of the improvement, when, after five days
of follow-up, there has been an improvement in three of
the four parameters evaluated: lung auscultation, radi-
ological evaluation of pulmonary infiltrate, arterial gaso-
metry and hematometry. Improvement is considered to
be early when it occurs within the first forty-eight hours
and late when it occurs later than this. Treatment is
considered to have failed when the patient does not
show improvement in three of the four parameters listed
above.
Respiratory Infection
Respiratory infection is defined by the presence of a
recent pulmonary infiltrate or an increase in pre-existing
infiltrate, in association with at least two or three clini-
cal criteria: a) fever (axillary temperature of 37.8°C), b)
changes in leukometry (leukocytes <4000 cel/mm3 or
>11000 cel/mm3), c) purulent tracheo-bronchial
secretion.
Duration of mechanical ventilation
The duration of mechanical ventilation outcome is eval-
uated according to whether the patient did or did not
require ventilator assistance for a continuous number of
days until fully taken off the ventilator.
Duration of intensive care unit (ICU) stay
The duration of ICU stay outcome is evaluated accord-
ing to whether the patient did or did not stay a continu-
ous number of days in the ICU before being definitively
discharged from the ICU.
Duration of hospital stay
The duration of hospital stay outcome is evaluated
according to whether or not the patient stay in hospital
for a continuous number of days before being defini-
tively discharged from hospital.
Occurrence of other infection-related complications
Occurrence of other infection-related complications may
be present when the patient is diagnosed as having
Table 2 Extent of lung involvement on respiratory
auscultation
Severity of lung
involvement
Extent of lung involvement on respiratory
auscultation
Slight Lower third
Moderate Lower two thirds
Severe Whole lung
Table 3 Extent of lung involvement according to
radiological examination
Severity of lung
involvment
Extent of lung involvement according to
radiological examination
Slight Lower third
Moderate Lower two thirds
Severe Whole lung
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monary abscess, tracheostomy wound infection, sepsis,
septic shock, or fungemia.
Other respiratory complications
The respiratory complications considered are atelectasis,
pneumothorax, broncospasms, bronco-aspiration, pneu-
momediastinum, subcutaneous emphysema,
hemothorax, decompensation of chronic obstructive pul-
monary disease, acute pulmonary embolism, and
empyema.
Adverse effects of methylprednisolone
Possible adverse effects of methylprednisolone include
gastro-intestinal bleeding with a drop in hematometry,
fungal infection, Herpes zoster, bacterial infection,
hyperglycemia, and systemic arterial hypertension (TA >
149 × 90 mmHg).
Population
Patients who fulfill the diagnostic criteria for leptospiro-
tic pneumonitis are included. Patients are excluded if
they are aged less than 15 years, have a history of hyper-
sensitivity to corticosteroids, have an active infection of
fungal, tuberculosis or bacterial origin other than the
leptospira infection, have hemoconcentration or lym-
phocytic atypia on admission to hospital, have co-mor-
bidities that may be responsible for changes in
radiological and gasometric examinations used to diag-
nose leptospirotic pneumonitis, present evidence of
recent cranial trauma, neurosurgery or a peptic ulcer, or
if they are taking part in another clinical trial.
Participant recruitment
The study will cover patients admitted to the intensive
care unit, or to the infectious diseases or internal medi-
cine ward in the Oswaldo Cruz University Hospital,
Barão de Lucena Hospital and Clinics University Hospi-
tal. During the study, the recruitment of patients from
other hospitals will be allowed.
Ethical considerations
The study was approved by the Research Ethics Com-
mittee, according to the resolutions of the National
Health Council (FR - 167386) and was monitored by an
external data monitoring committee throughout.
Sample size
The sample size was calculated on the basis of a statisti-
cal significance (alpha error) of 5%, a power of 80%, cor-
responding to a beta error of 20%. The expected
mortality for leptospirotic pneumonitis is 30%. For a
reduction of 50% in mortality, the expected mortality in
patients treated with corticosteroids would be 15%. The
sample size calculated was 133 patients for each group.
The same parameters were used to obtain statistical
significance and a standard deviation of 21 days for
duration of mechanical ventilation, giving an expected
sample of 33 patients per group. For the duration of
ICU stay variable, the same parameters were used to
obtain statistical significance and a standard deviation of
8 days, giving an expected sample of 23 patients per
group.
Randomization
The patients with clinical symptoms of leptospirosis
admitted to ICUs and hospital wards covered by the
study are evaluated by doctors involved in the study to
establish the extent to which they meet the criteria for
diagnosis of leptospirosis and leptospirotic pneumonitis.
Once this has been established, the patient is informed
of the study and inclusion depends on his or her con-
sent (signed informed consent), or, if this is not possible,
on that of their relatives or legal guardians. The rando-
mization was carried out in advance by drawing lots.
The groups to which the patients are allocated are
placed in sealed numbered envelopes that are only
opened after the informed consents have been signed.
The envelopes are opened by a third party not involved
in assistance of the patients. Block randomization within
each severity stratum is performed in each hospital unit.
The degree of severity is stratified according to the
APACHE II score. Blocks of ten are used.
Operationalization of the Study
The study involves three hospitals and their respective
intensive care units and wards for internal medicine and
infectious diseases. A coordinating physician is assigned
to each hospital to organize evaluation, inclusion and
follow-up of the patients for the duration of the study.
Two supervising doctors oversee the development of the
study by way of monthly meetings with the coordinators
of each hospital. To ensure that the study is double-
blind, the preparation of the methylprednisolone and of
the placebo is carried out in each hospital’s pharmacy,
duly coded and known only to the nurse involved in the
study. The patients in the control group receive an infu-
sion of saline solution identical in volume to that of the
dilution received by the intervention group. The nurse
involved in the study fill in a card identifying which
patients received the placebo and which the methylpred-
nisolone. This card is stored by a physician who did not
treat the patients nor takes part in the investigation and
will only be opened at the end of the study.
Standardization of Treatments
All the patients included receive the conventional treat-
ment for leptospirosis, which is the basic care provided
for severely ill patients, such as volemic reposition, anti-
biotics, control of hemodynamics, correction of
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hemoderivatives, hemodialysis, early and adequate nutri-
tion, oxygen treatment, and artificial ventilation, when
necessary, along with others that are commonly recom-
mended. Decisions regarding the use of drugs and inva-
sive or non-invasive procedures are taken by the
patients’ attending physicians, in accordance with cur-
rent good medical practice, based on data from the lit-
erature. In view of the high doses of corticosteroid used,
all patients are given an anti-parasitic drug (albendazol)
and gastric protection (H2 blocker). The specific items
of the treatment of leptspirosis are standardized as fol-
lows:
￿ Volemic reposition and the use of vasoactive drugs
for lungs congested by pneumonitis follow the cri-
teria established in the algorithms given in Appen-
dices II and III.
￿ Treatment with antibiotics involves the administra-
tion of crystalline penicillin at a dose of 1,500,000
international units every six hours for all patients,
r e g a r d l e s sh o wl o n gt h e yh a v eh a dt h ed i s e a s e ,o r
with a 1 g dose of ceftriaxone every twenty-four
hours in those allergic to penicillin or where the use
of penicillin is not possible. Antimicrobial treatment
for associated infections is carried out according to
specific recommendations
13,14,31.
￿ The recommendation for platelet transfusion is
calculated on the basis of one unit of platelet con-
centrate per 10 kg of the patient’s weight, every
twelve or eight hours, according to the following cri-
teria: a platelet count (PC) less than or equal to
20,000/mm
3 even in the absence of bleeding; a PC
of less than or equal to 50,000/mm
3 in cases of
more severe bleeding and/or when invasive surgery
or biopsies are required
15 and PC <100,000/mm
3 in
cases where major surgery has been performed.
￿ Hemodialysis is carried out according to the
recommendations outlined in the algorithms con-
tained in Appendices II and III.
￿ Mechanical ventilation, where necessary, is used in
controlled volume mode (VCV with a flow rate of 6
ml/kg, to generate a maximum plateau pressure of
30 cmH2O and a maximum inspiratory peak of 45
cmH2O) or controlled pressure (PCV with maximum
pressure of 30 cmH2O), and with final positive
expiratory pressure sufficient to maintain the lowest
possible fraction of inspired oxygen (FiO2)( t h ei d e a l
PEEP calculated according to the routine of the hos-
pital ubit: PEEP curve X static complacency; pres-
sure curve X volume; or a test of different PEEPs
under SpO2 monitoring)
2,3,18,42.
Statistical analysis
Double data enter is performed using EPI INFO Version
6.0, giving rise to two datasets that can be compared to
detect possible typing errors. The dataset is subse-
quently checked for consistency. The distribution of
potential confounding factors in the two treatment
groups are compared to check randomization.
The main analysis will be carried out through compar-
ison of the various outcomes in the two groups, by cal-
culating the percentage distribution and the relative risk.
The 95-% confidence interval and the chi-squared test
will be used to test statistical association. The t-test will
be used to compare the means. The results are consid-
ered statistically significant when the p-value is less than
0.05. The efficacy of the intervention is calculated
according to the following formula:
% treatment failure in control group − % treatment failure in intervention group
% treatment failure in control group
Patients randomly included in the study who, for
whatever reason, including transfer to another hospital,
do not receive the treatment for which they were
assigned are considered to belong to the group to which
they were allocated (intention to treat analysis).T h e s e
will be deemed treatment failure. The patients who do
not receive confirmation from the laboratory of diagno-
sis of leptospirosis will still be included in the analysis.
T h e yw i l ln o tb ec o n s i d e r e da s losses or treatment fail-
ure. Data analysis will be carried out using EPI INFO
Version 6.0 and SPSS 8.0.
Discussion
Lung involvement in leptospirosis is a serious manifesta-
tion, with a high and variable mortality rate. There is
still no specific cleary-established treatment. Well-
designed studies are needed to pave the way towards
development of such a treatment.
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